Development and validation of analytical methodology for quantification of propranolol hydrochloride in a multiparticulate biphasic system by UV-vis spectrophotometry

Hypertension is one of the most important mortality risks in the world and is considered the leading cause of deaths associated with cardiovascular disease. In an attempt to improve the treatments and apply them to a large number of disorders, a propranolol hydrochloride (Prop) based medicine it was developed in our laboratory, employing a multiparticulate system which operates in a biphasic manner, one portion of immediate and other of modified release. This study aimed at developing and validating a suitable method to quantify this new version of the drug using UV spectrophotometry, following what is recommended in RE 899/2003. The results showed that the method employed was linear, accurate, precise and robust in the range of 0.8 to 96.0 μg mL-1, which allows it for routine use in quality control laboratories.